New Risk • Aug 16
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings are forecast to decline by an average of 2.4% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$1.34m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Annonce • Aug 05
Aethlon Medical, Inc. to Report Q1, 2027 Results on Aug 13, 2026 Aethlon Medical, Inc. announced that they will report Q1, 2027 results at 4:15 PM, US Eastern Standard Time on Aug 13, 2026 Annonce • Jul 13
Aethlon Medical, Inc. Continues Enrollment And Reports Directional Changes In Second Cohort Of Australian Oncology Clinical Trial Evaluating Hemopurifier Aethlon Medical, Inc. announced that patients in the second cohort of its Australian oncology feasibility study demonstrated biological changes consistent with those previously observed in the first cohort following treatment with the investigational Hemopurifier. Replicating these findings in a second group of patients strengthens the scientific rationale for the Company's ongoing clinical program and supports continued enrollment in the third and final cohort before an independent statistical analysis is conducted. The Australian feasibility study is evaluating the safety, feasibility and dosing of the Hemopurifier in patients with advanced solid tumors whose cancers have progressed despite treatment with anti-PD-1 immunotherapies. The second cohort continued to show directional changes in several biomarkers that researchers believe are associated with tumor growth, immune suppression and response to immunotherapy, including: Reductions in tumor-derived extracellular vesicles (EVs), platelet-derived EVs and PD-L1-positive EVs, with these changes appearing more consistently across all participants than in the first cohort and generally persisting through the eight-week follow-up period. Reductions in two microRNAs that have been associated with tumor growth and cancer invasion. Improvements in multiple immune-related laboratory ratios—including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), Systemic Immune-Inflammation Index (SII), monocyte-to-albumin ratio (MAR) and Lymphocyte Albumin Index (LAI)—that have been associated in published research with improved responses to immunotherapy. Increases in total T cells, CD4 and CD8 T-cell populations, and tumor-specific CD137-positive T cells in all three participants, with these changes generally persisting through the eight-week follow-up period. Taken together, the first two cohorts have now shown similar directional changes across multiple biological markers following Hemopurifier treatment. Enrollment in the third cohort is underway, with the first participant having already completed three four-hour Hemopurifier treatments during a one-week period. After all three cohorts are complete, an independent statistician will analyze the combined data to determine whether these observations support a dose-response relationship. EVs continue to be recognized as important drivers of cancer progression and resistance to checkpoint inhibitors such as Keytruda and Opdivo. The Hemopurifier is designed to remove these tumor-derived vesicles from the bloodstream, with the goal of reducing immune suppression and potentially enhancing the body's ability to fight cancer. Extracellular vesicles released by tumors continue to be recognized as important drivers of cancer progression, metastasis and resistance to immunotherapy. EVs expressing PD-L1 have been associated with resistance to checkpoint inhibitors, including Keytruda and Opdivo. The Hemopurifier is designed to remove tumor-derived EVs and other pathogenic particles from circulation, potentially reducing immunosuppressive signaling and improving the body's anti-tumor immune response. The Hemopurifier has received FDA Breakthrough Device Designation for the treatment of patients with advanced or metastatic cancer who are unresponsive or intolerant to standard-of-care therapy, as well as for the treatment of life-threatening viral infections not addressed by approved therapies. The Company cautions that these findings represent descriptive observations from raw data generated in an early-stage feasibility study. Formal statistical analyses have not yet been performed and will be conducted only after completion of all three study cohorts by an independent statistician. The study was not designed to demonstrate clinical efficacy, and no conclusions can be drawn regarding the Hemopurifier's impact on patient outcomes. Larger, adequately powered clinical trials designed with clinical efficacy endpoints will be required to determine whether the biological changes observed translate into meaningful clinical benefit. Annonce • Jun 24
Aethlon Medical, Inc. has filed a Follow-on Equity Offering. Aethlon Medical, Inc. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 6,000,000
Price\Range: $2
Discount Per Security: $0.13
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 6,000,000
Price\Range: $1.99
Discount Per Security: $0.13
Security Name: Warrants
Security Type: Equity Warrant
Securities Offered: 6,000,000
Transaction Features: Registered Direct Offering New Risk • Jun 11
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.9m free cash flow). Earnings are forecast to decline by an average of 1.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.17m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$16m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Annonce • Jun 02
Aethlon Medical, Inc. to Report Fiscal Year 2026 Results on Jun 10, 2026 Aethlon Medical, Inc. announced that they will report fiscal year 2026 results at 4:15 PM, US Eastern Standard Time on Jun 10, 2026 New Risk • May 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.9m free cash flow). Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.84m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Annonce • Mar 25
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Aethlon Medical, Inc. announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. The trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors Who Have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab", is being conducted to assess the Hemopurifier's safety, feasibility, and optimal dosing. The DSMB, comprised of independent medical experts in nephrology and oncology, reviewed data from participants enrolled in the second cohort, in which patients received two Hemopurifier treatments over a one-week period. Based on their evaluation, the DSMB found no safety concerns and confirmed that the Hemopurifier continues to demonstrate a favorable safety and tolerability profile. To date, no serious adverse events (SAEs) or Dose-Limiting Toxicities (DLTs) related to the Hemopurifier device or treatment have been reported. Enrollment for Cohort 3 is now open. In this final cohort, participants will receive three Hemopurifier treatments over a one-week period further evaluating safety, feasibility and dosing parameters at the study's three active clinical sites in Australia. This trial is designed to enroll approximately 9 to 18 patients with solid tumors who have stable or progressive disease, while receiving treatment that includes Pembrolizumab (Keytruda®) or Nivolumab (Opdivo®). The primary endpoint of this trial is the incidence of adverse events and clinically significant changes in safety laboratory tests of Hemopurifier-treated patients. In addition to safety monitoring, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of extracellular vesicles (EVs) and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These findings are expected to inform the design of a future efficacy and safety, Premarket Approval (PMA), study required by regulatory authorities. The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects. The Hemopurifier holds a U.S. Food and Drug Breakthrough Device for the treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies. The Hemopurifier is being developed under an open Investigational Device Exemption (IDE) for both indications. New Risk • Feb 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.1m free cash flow). Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (439% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$1.91m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$20m net loss in 3 years). Share price has been volatile over the past 3 months (16% average weekly change). Annonce • Feb 04
Aethlon Medical, Inc. to Report Q3, 2026 Results on Feb 12, 2026 Aethlon Medical, Inc. announced that they will report Q3, 2026 results at 4:15 PM, US Eastern Standard Time on Feb 12, 2026 Annonce • Jan 19
Aethlon Medical, Inc., Annual General Meeting, Feb 19, 2026 Aethlon Medical, Inc., Annual General Meeting, Feb 19, 2026. Annonce • Dec 24
Aethlon Medical, Inc. announced that it has received $2.1537 million in funding On December 23, 2025, Aethlon Medical, Inc. closed the transaction. The company raised the proceeds pursuant to Regulation D from single investor. The company paid $214,500 as a sales commission Maxim Group, LLC has the option to subscribe for and purchase up to 96,059 shares of Common Stock.. Annonce • Dec 02
Aethlon Medical, Inc. Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier Aethlon Medical, Inc. announced the 20 November 2025 publication of a pre-clinical study entitled " Increased mannosylation of extracellular vesicles in Long COVID plasma provides a potential therapeutic target for Galanthus nivalis agglutinin (GNA) affinity resin" in the pre-print online archive bioRxiv: This paper has simultaneously been submitted for consideration to a peer-reviewed journal. The use of Pathway activity interference software indicated that removal of these microRNAs may be associated with downregulation of inflammatory pathways, including JAK-STAT, and upregulation of tissue repair pathways. New Risk • Nov 19
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.1m free cash flow). Share price has been highly volatile over the past 3 months (36% average weekly change). Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (336% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.08m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$20m net loss in 3 years). Annonce • Nov 07
Aethlon Medical, Inc. to Report Q2, 2026 Results on Nov 12, 2025 Aethlon Medical, Inc. announced that they will report Q2, 2026 results at 4:15 PM, US Eastern Standard Time on Nov 12, 2025 Annonce • Oct 23
Aethlon Medical, Inc. Receives Letter from Nasdaq for Non-Compliance to Continued Listing On October 16, 2025, Aethlon Medical, Inc. (the Company") received a notification letter (the Notice") from the Listing Qualifications Department (the Staff") of the Nasdaq Stock Market LLC (Nasdaq") notifying the Company that, because the closing bid price for the Company's common stock was below $1.00 per share for 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the Minimum Bid Price Requirement") and subject to the compliance and delisting provisions of Rule 5810(c)(3)(A) and (iv) thereunder. The Company has filed a request for a hearing before the Nasdaq Hearings Panel (the Panel"). The hearing request will automatically stay any suspension or delisting action by Nasdaq pending the panel's decision, and the Company's common stock will continue to trade on Nasdaq Capital Market under the symbol AEMD". As part of its plan to regain compliance with Nasdaq listing requirements, the Company has already implemented a 1-for-10 reverse stock split of its common stock, which became effective on October 16 and began trading on October 20, 2025. The Company is monitoring the closing bid price of its common stock and will evaluate additional actions as appropriate to maintain its listing on the Nasdaq Capital Market. Annonce • Oct 07
Aethlon Medical, Inc. Provides Observations on the Preliminary Changes in Extracellular Vesicle (EV), MicroRNA and Lymphocyte Counts in the First Patient Cohort in its Ongoing Oncology Clinical Trial in Australia Aethlon Medical, Inc. provided observations on the preliminary changes in extracellular vesicle (EV), microRNA and lymphocyte counts in the first patient cohort in its ongoing oncology clinical trial in Australia. The study is a safety, feasibility, and dose-finding trial evaluating the company's Hemopurifier (HP) in patients with cancer not responding to anti-PD-1 therapy. In the initial three patients, there were encouraging changes in extracellular Vesicles (EVs), microRNAs, and lymphocytes, following a single Hemopurifier treatment. The company observed interesting directional changes in EV numbers, microRNAs and lymphocytes following a single Hemopurifiers treatment in the three participants in the first cohort. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses, fragments of viruses, and EVs has been demonstrated in both in vitro studies and in human patients. The Hemopurifier®? holds a U.S. Food and Drug Breakthrough Device Designation for: The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies. Annonce • Aug 05
Aethlon Medical, Inc. to Report Q1, 2026 Results on Aug 13, 2025 Aethlon Medical, Inc. announced that they will report Q1, 2026 results at 4:15 PM, US Eastern Standard Time on Aug 13, 2025 Annonce • Jul 15
Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort Aethlon Medical, Inc. announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review and recommended advancing to the next patient cohort without modification. The trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid tumors who have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab", is being conducted to assess the Hemopurifier's safety, feasibility, and optimal dosing. The DSMB- comprising independent medical experts in nephrology and oncology- reviewed data from the initial cohort of three participants, each of whom received a single 4-hour Hemopurifier treatment. Based on their evaluation, the board found no safety concerns and confirmed that the Hemopurifier continues to demonstrate a favorable safety and tolerability profile. The primary endpoint of this trial is the incidence of adverse events and clinically significant changes in safety laboratory tests of Hemopurifier- treated patients. In addition to safety monitoring, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These findings are expected to inform the design of a future efficacy and safety, Premarket Approval (PMA), study required by regulatory authorities. Aethlon Medical, Inc. remains committed to advancing the Hemopurifier for use in oncology and will continue to provide updates as the clinical trial progresses. The Aethlon Hemopurifiers is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects. The Hemopurifier holds a U.S. Food and Drug Breakthrough Device for: The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and The treatment of life-threatening viruses not addressed with approved therapies. The Hemopurifier is being developed under an open Investigational Device Exemption (IDE) for both indications. New Risk • Jul 07
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 9.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.6m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 9.2% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (US$2.49m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$21m net loss in 3 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Price Target Changed • Jul 07
Price target decreased by 33% to US$3.03 Down from US$4.50, the current price target is an average from 2 analysts. New target price is 159% above last closing price of US$1.17. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$2.06 next year compared to a net loss per share of US$8.58 last year. New Risk • Jun 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.5m free cash flow). Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (124% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$4.18m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$11m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Annonce • Jun 20
Aethlon Medical, Inc. to Report Q4, 2025 Results on Jun 26, 2025 Aethlon Medical, Inc. announced that they will report Q4, 2025 results at 4:15 PM, US Eastern Standard Time on Jun 26, 2025 Annonce • Jun 18
Aethlon Medical Treats Second Patient in Australian Hemopurifier Cancer Trial Aethlon Medical, Inc. announced a significant milestone: the treatment of the second patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda®? (pembrolizumab) or Opdivo®? (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was treated with the Hemopurifier June 11, 2025 by Genesis Care and Royal North Shore Hospital/University of Sydney. Professor Stephen Clarke, Medical Oncologist, is the Principal Investigator for the study and the Hemopurifier session was supervised by Dr. Emma O'Lone. Participants # 2 was treated with the HemopURifier at Royal North Shore/University of Sydney on June 2, 2025. Both participants completed the 4-hour Hemopurifier treatment without device deficiencies or immediate complications. As of June 10, 2025, both patients have completed the pre-specified 7-day safety follow-up period that will be presented to an independent Data Safety Monitoring Board (DSMB) following the treatment of a third patient in the cohort. The DSMB will review safety data on this first cohort and provide a recommendation to Aethlon Medical Senior Leadership about advancing to the second treatment cohort where 3 participants will receive 2 Hemopurifier treatments during a one-week period. The company would expect data on extracellular removal by the Hemopurifier and effects on anti-tumor T cell activity on participants in the first cohort in approximately three months following enrollment of the third patient. Extracellular vesicles released from solid tumors have been implicated in the spread of cancers known as metastasis as well as in the resistance to immunotherapy and chemotherapeutic agents. Removal of enveloped viruses and extracellular vesicles has been observed in vitro studies and in human subjects. The Hemopurifier holds a U.S. Food and Drug Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to orolerant of standard-of-care therapy. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Annonce • Jun 10
Aethlon Medical to Present New Pre-Clinical Data At the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes Aethlon Medical, Inc. announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025. Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Aethlon Medical's Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose. The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered from COVID-19 in order to examine whether individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively. Presentation details and times are as follows: Extracellular Vesicles from Participants with Long COVID are Mannosylated and Bind to the Galanthus Nivalis Agglutinin Resin in the Aethlon Hemopurifier®. Annonce • May 15
Aethlon Medical, Inc. Announces Publication of Preclinical Data Showing Ability of the Hemopurifier to Remove Platelet-Derived Extracellular Vesicles from Plasma Aethlon Medical, Inc. announced the publication of a pre-clinical ex vivo study in pre-print vehicle bioRxiv, entitled, "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin." Aethlon Medical's Hemopurifier®? is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles (EVs or exosomes) and life-threatening viruses from blood and other biological fluids, properties that support its evaluation not only in oncology and infectious diseases, but also in the organ transplantation and other areas of significant unmet medical need. The company hypothesized that the Aethlon Hemopurifier, which contains a proprietary GNA affinity resin would remove platelet derived EVs from plasma. In this experiment two hundred milliliters of donated healthy human plasma were circulated over the Aethlon Hemoupurifier (HP) to simulate a clinical HP session. The study results indicated a 98.5% removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment. Next steps will be to submit the findings of this study to a peer-review medical journal and specifically study PD-EV removal and their cargo from plasma samples from diseases of interest. Annonce • Mar 11
Aethlon Medical, Inc. Publishes Preclinical Data on the Hemopurifier in Transplant Immunology Journal Aethlon Medical, Inc. announced the publication of a pre-clinical study in the peer-reviewed journal Transplant Immunology on February 28, 2025, entitled, " A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys." Aethlon Medical's Hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles and life-threatening viruses from blood and other biological fluids. Its capabilities have potential applications in oncology and infectious diseases, and organ transplantation. The use of machine perfusion of recovered organs as opposed to cold storage has helped but there is still room for improvement. The release of extracellular vesicles (EVs) and microRNAs from the donor kidney are hypothesized to play a role in these complications. With that in mind, the company specifically examined the ability of the Hemopurifier to remove EVs and noxious microRNAs from the perfusion fluid from discarded kidneys that had undergone Controlled Oxygenated Rewarming. The company demonstrated significant reductions in EVs as well as microRNAs implicated in renal dysfunction. Price Target Changed • Feb 20
Price target decreased by 45% to US$3.88 Down from US$7.05, the current price target is an average from 2 analysts. New target price is 536% above last closing price of US$0.61. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.73 next year compared to a net loss per share of US$4.86 last year. Annonce • Feb 05
Aethlon Medical, Inc. to Report Q3, 2025 Results on Feb 12, 2025 Aethlon Medical, Inc. announced that they will report Q3, 2025 results at 4:15 PM, US Eastern Standard Time on Feb 12, 2025 Annonce • Jan 29
Aethlon Medical Treats First Patient in Australian Hemopurifier Cancer Trial Aethlon Medical, Inc. announced a significant milestone: the treatment of the first patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia, and treated with the Hemopurifer on January 29, 2025, by Prof. Toby Coates and the dialysis staff. The patient treated was determined to have progressive disease following a two-month "run -in" period of the anti-PD-1 drug Nivolumab. During this period, serial measurements of extracellular vesicles (EVs) and anti-tumor T cell activity were obtained. The patient was then treated with the Aethlon Hemopurifier for 4 hours on a single day and tolerated the procedure without complications. The patient will have follow-up safety visits, EV and T cell measurements as well as imaging for clinical response. Currently, only approximately 30-40% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. EVs produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes from the plasma of cancer patient samples. The primary endpoint of the approximately 18-patient, safety, feasibility, and dose-finding trial is the incidence of adverse events and clinically significant changes in safety lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run-in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2, or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies. Annonce • Jan 09
Aethlon Medical Receives Extension Notice from Nasdaq to Regain Compliance with the Minimum Bid Price Requirement As previously reported, on June 27, 2024, Aethlon Medical Inc., a Nevada Corporation (the Company") received a letter (the Notice") from The Nasdaq Stock Market (Nasdaq") advising the Company that for 31 consecutive trading days preceding the date of the Notice, the bid price of the Company's common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2)(the Minimum Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until December 24, 2024, to regain compliance with the Minimum Bid Requirement. On January 7, 2025, the Company received a letter from Nasdaq (the Extension Notice") advising that the Company has been granted a 180-day extension, or until June 23, 2025, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to June 23, 2025, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive trading days, the Company will regain compliance with the Minimum Bid Price Requirement. The Extension Notice has no immediate effect on the listing of the Company's common stock on The Nasdaq Capital Market and does not affect the Company's reporting requirements with the Securities and Exchange Commission. If the Company does not regain compliance with the Minimum Bid Price Requirement during the additional 180-day extension, Nasdaq will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set in the applicable Nasdaq Listing Rules. However, there can be no assurance that, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the additional 180-day compliance period ending June 23, 2025 or maintain compliance with any other Nasdaq listing requirement. The Company intends to monitor the closing bid price of common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement. Annonce • Dec 28
Aethlon Medical, Inc. has filed a Follow-on Equity Offering. Aethlon Medical, Inc. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 20,000,000
Price\Range: $0.6 to $1
Discount Per Security: $0.057
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 20,000,000 Annonce • Dec 21
Aethlon Medical, Inc. Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu Aethlon Medical, Inc. provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu." Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the treatment of Bird Flu. These inquiries come on the heels of the reporting of isolation of Bird Flu in dairy cows, 60 human cases in eight states including a case of severe infection in Louisiana, and declaration of a state of emergency in California. The Aethlon Hemopurifier is an investigational extracorporeal medical device designed to remove enveloped viruses and extracellular vesicles from the bloodstream. The device incorporates plasma separation, size exclusion, and affinity binding to a proprietary resin containing the plant lectin Galanthus nivalis agglutinin (GNA) bound to a medical grade diatomaceous earth. Enveloped viruses and extracellular Vesicles contain the sugar mannose on their surface, which is the therapeutic target of the GNA. Aethlon has previously contracted Battelle labs to examine the in vitro removal of influenza viruses including H5N1 by a scaled down version of the Aethlon Hemopurifiers. In this experiment, cell culture media was spiked with the H5N1 virus and continuously circulated over the device. Samples were taken periodically to examine antiviral removal by the device. In this study, a miniature version of the device removed 99% of H5N1 following 6 hours of treatment. While the Aethlon HemopURifier has not yet been used to treat patients with severe influenza, including those infected with H5N1, it has been used in 38 patients across 164 distinct treatment sessions, targeting diseases such as hepatitis C, HIV, and in patients critically ill due to COVID-19 and Ebola. The Hemopurifier has a "breakthrough device" designation with the FDA for life-threatening viruses for which there is no effective treatment. Current treatment guidelines from the Center for Disease Control and Prevention, for hospitalized patients with suspected Bird Flu (H5N1), are to initiate antiviral therapy as soon as possible with Oseltamivir, with or without combination therapy with Baloxavir. Clinical failures during Oseltamavir therapy due to the development of antiviral resistance have been observed in hospitalized patients with H5N1. This phenomenon raises the possibility that novel treatment strategies may be required. Aethlon Medical will monitor this situation closely and interact with hospitals, the state of California, and the FDA as appropriate if cases mount and currently available treatments are not effective. Price Target Changed • Nov 20
Price target decreased by 45% to US$3.85 Down from US$7.05, the current price target is an average from 2 analysts. New target price is 887% above last closing price of US$0.39. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$0.97 next year compared to a net loss per share of US$4.86 last year. New Risk • Nov 15
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 4.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 4.5% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (459% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$5.55m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$12m net loss next year). Annonce • Nov 12
Aethlon Medical Announces Enrollment of the First Patient in (FPI) Its Hemopurifier Cancer Trial in Australia Aethlon Medical, Inc. announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia. The first patient completed screening activities confirming their eligibility on November 8, 2024, and has now entered a two-month run-in period, receiving anti-PD-1 therapy. During this time, concentrations of Extracellular vesicles (EVs) and anti-tumor T cell activity will be measured. If imaging after this two-month run-in period reveals no improvement in the patient's tumor, they will be treated with the Hemopurifier, followed by monitoring to identify decreases in EV concentrations and improvements in T cell anti-tumor activity. Currently, only approximately 30% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. EVs produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes from the plasma of cancer patient samples. The primary endpoint of the approximately nine to 18-patient, safety, feasibility and dose-finding trial is the incidence of adverse events and clinically significant changes in safety lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2 or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies. Annonce • Nov 06
Aethlon Medical, Inc. to Report Q2, 2025 Results on Nov 13, 2024 Aethlon Medical, Inc. announced that they will report Q2, 2025 results at 4:15 PM, US Eastern Standard Time on Nov 13, 2024 Annonce • Sep 19
Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier Cancer Trial in India Aethlon Medical, Inc. announced that, on September 9, 2024, the Medanta Institutional Ethics Committee (MIEC) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda (pembrolizumab) or Opdivo (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for one year, followed by annual reviews. This trial has previously been reviewed by the Institutional Review Board at Medanta. Additionally, the company previously received a No Objection Certificate (NOC) from DCGI (the Indian Regulatory Authority) for the proposed oncology trial. The trial will be conducted by Dr. Ashok K. Vaid and his staff at the Department of Medical Oncology and Hematology at Medanta Medicity Hospital in Gurugram, India. The Hemopurifier treatments will be performed by Dr. Puneet Sodhi from the Department of Nephrology, who has conducted more Hemopurifier treatments than anyone else in the world. At present, only approximately 30% of cancer patients who receive pembrolizumab or nivolumab treatment for solid tumors will have lasting clinical responses to these agents. Extracellular vesicles (EVs) produced by tumors have been implicated in resistance to anti-PD-1 therapies as well as the spread of cancers. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of EVs in cancer patient plasma samples. The primary endpoint of the approximately nine to 18-patient, safety, feasibility and dose-finding trial is safety. The trial will monitor any adverse events and clinically significant changes in lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run in period of PD-1 antibody, Keytruda or Opdivo monotherapy. Patients who do not respond to the PD-1 therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2 or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies. Annonce • Sep 18
Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial Aethlon Medical, Inc. announced that the Cancer Clinical Trial Unit at Royal Adelaide Hospital was activated on September 10, 2024 to begin screening and enrolling patients in its safety, feasibility and dose-finding clinical trial of the Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda (pembrolizumab) or Opdivo (nivolumab) (AEMD-2022-06 Hemopurifier Study). The trial will be conducted by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia. The activation follows the previously announced approval by the Human Research Ethics Committee at Central Adelaide Local Health Network on June 13, 2024, and the Research Governance office at Royal Adelaide Hospital, on September 3, 2024, as well as the notification of the Therapeutic Good Administration (TGA) and completion of a Site Initiation Visit on September 9, 2024. Currently, only approximately 30% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. Extracellular vesicles (EVs) produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes from the plasma of cancer patient samples. The primary endpoint of the approximately 18-patient, safety, feasibility and dose-finding trial is the incidence of adverse events and clinically significant changes in safety lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run in period of PD-1 antibody, Keytruda or Opdivo monotherapy. Patients who do not respond to the therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2 or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and whether these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies. Annonce • Aug 28
Aethlon Medical, Inc. Announces Publication of Preclinical Data Showing Ability of the Hemopurifier to Remove Extracellular Vesicles and MicroRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Donor Kidneys Aethlon Medical, Inc. announced the publication in preprint of an in vitro study in bioRxiv on August 24, 2024, entitled, "The Hemopurifier Removes Extracellular Vesicles and microRNAs From Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys." Aethlon Medical's Hemopurifier is a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids, qualities which have potential applications in oncology and infectious diseases, as well as in the organ transplant setting. Given that one approach to lessen these complications and potentially increase the time of assessment of organ viability is to use machine perfusion on recovered kidneys, and, based on Aethlon Medical's prior data in COVID-19 and oncology, it was hypothesized that the Hemopurifier could remove EVs and microRNAs from renal perfusates. In this proof-of-concept study, the company obtained four perfusates from discarded donor kidneys that had undergone a type of machine perfusion called Controlled Oxygenated Rewarming (COR). These perfusates were then pumped over the Hemopurifier and analyzed for EV counts and microRNA levels. The results confirmed the removal of both small and larger size EVs and a significant reduction in microRNAs. Annonce • Aug 16
Aethlon Medical, Inc., Annual General Meeting, Sep 27, 2024 Aethlon Medical, Inc., Annual General Meeting, Sep 27, 2024. Annonce • Aug 13
Aethlon Medical, Inc. Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial Aethlon Medical, Inc. announced that, on August 6, 2024, the Bellberry Human Research Ethics Committee (BHREC) granted full ethics approval to the Pindara Private Hospital for a safety, feasibility and dose-finding clinical trial of the Hemopurifier®? in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Merck's Keytruda®? (pembrolizumab) or Bristol Myers Squibb's Opdivo®? (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for one year, until August 6, 2025. The trial will be conducted by Dr. Marco Matos and his staff at the Pindara Private Hospital, located in Queensland, Australia. Currently, only approximately 30% of cancer patients who receive pembrolizumab or nivolumab treatment for solid tumors will have lasting clinical responses to these agents. Extracellular vesicles (EVs) produced by tumors have been implicated in resistance to anti-PD-1 therapies as well as the spread of cancers. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes in cancer patient plasma samples. The primary endpoint of the approximate nine to 18-patient, safety, feasibility and dose-finding trial is safety. The trial will monitor any adverse events and clinically significant changes in lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the PD-1 therapy will be eligible to enter the Hemopurifier period of the study, where sequential cohorts will receive 1, 2 or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies. Annonce • Aug 06
Aethlon Medical, Inc. to Report Q1, 2025 Results on Aug 14, 2024 Aethlon Medical, Inc. announced that they will report Q1, 2025 results at 4:15 PM, US Eastern Standard Time on Aug 14, 2024 Annonce • Jun 22
Aethlon Medical, Inc. to Report Fiscal Year 2024 Results on Jun 27, 2024 Aethlon Medical, Inc. announced that they will report fiscal year 2024 results at 4:15 PM, US Eastern Standard Time on Jun 27, 2024 Annonce • Jun 18
Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier® Cancer Trial Aethlon Medical, Inc. announced that, on June 13, 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier®? in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda®? (pembrolizumab) or Opdivo®? (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for three years, until June 13, 2027. The trial will be conducted by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital, located in Adelaide, Australia. Currently, only approximately 30% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. Extracellular vesicles (EVs) produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premieret Approval (PMA), study required by regulatory agencies. Annonce • Jun 05
Aethlon Medical, Inc. Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies Aethlon Medical, Inc. provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®. continue to make progress preparing for planned, safety, feasibility and "dose finding" oncology trials in Australia and India, and want to provide shareholders and other constituents with an update, stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. In early May, announced new data showing the in vitro removal of exosomes from cancer patient plasma using a miniature version of Hemopurifier®. This data has been quickly integrated into the required documentation for Ethics Committees at potential clinical sites. On May 17, 2024, provided these documents to the Contract Research Organizations for these planned clinical trials. Subsequently, on May 24, 2024, one potential site submitted the documents to its Ethics Board. An additional site in Australia and another in India are currently assembling the packages for submission to their Ethics Committees. Once receive the expected Ethics Committee approvals, will finalize the Clinical Trial Agreements. After this, hospitals can begin recruiting patients for the trials. As a reminder, the target patient population for these safety, feasibility, and dose finding trials is oncology patients with solid tumors who are failing their anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®. New Risk • May 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 302% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 6.3% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (302% increase in shares outstanding). Revenue is less than US$1m (US$574k revenue). Market cap is less than US$10m (US$3.88m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$13m net loss next year). Annonce • May 18
Aethlon Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.69235 million. Aethlon Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.69235 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,450,000
Price\Range: $0.58
Discount Per Security: $0.0377
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 5,650,000
Price\Range: $0.579
Discount Per Security: $0.0377
Security Name: Class A Warrants
Security Type: Equity Warrant
Securities Offered: 8,100,000
Security Name: Class B Warrants
Security Type: Equity Warrant
Securities Offered: 8,100,000 New Risk • May 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 6.3% per year for the foreseeable future. Revenue is less than US$1m (US$574k revenue). Market cap is less than US$10m (US$2.23m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$13m net loss next year). Shareholders have been diluted in the past year (14% increase in shares outstanding). Annonce • May 11
Aethlon Medical, Inc. Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma Aethlon Medical, Inc. announced positive results from an in vitro binding study of its Hemopurifier in removing extracellular vesicles (EVs) from plasma. The translational study provides pre-clinical evidence to support Aethlon's planned phase 1 safety, feasibility and dose-finding clinical trials of the Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda or Opdivo. Annonce • Mar 23
Aethlon Medical, Inc. has filed a Follow-on Equity Offering in the amount of $16.32 million. Aethlon Medical, Inc. has filed a Follow-on Equity Offering in the amount of $16.32 million.
Security Name: Common Stock
Security Type: Common Stock
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Security Name: Warrants
Security Type: Equity Warrant Price Target Changed • Mar 04
Price target increased by 27% to US$40.10 Up from US$31.55, the current price target is provided by 1 analyst. New target price is 2,330% above last closing price of US$1.65. Stock is down 66% over the past year. The company is forecast to post a net loss per share of US$5.22 next year compared to a net loss per share of US$5.86 last year. Annonce • Feb 08
Aethlon Medical, Inc. to Report Q3, 2024 Results on Feb 14, 2024 Aethlon Medical, Inc. announced that they will report Q3, 2024 results at 4:15 PM, US Eastern Standard Time on Feb 14, 2024 New Risk • Nov 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Earnings are forecast to decline by an average of 15% per year for the foreseeable future. Revenue is less than US$1m (US$574k revenue). Market cap is less than US$10m (US$4.28m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$14m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (8.2% increase in shares outstanding). Annonce • Nov 07
Aethlon Medical, Inc. to Report Q2, 2024 Results on Nov 14, 2023 Aethlon Medical, Inc. announced that they will report Q2, 2024 results at 4:15 PM, US Eastern Standard Time on Nov 14, 2023 Price Target Changed • Oct 25
Price target decreased by 21% to US$31.55 Down from US$40.10, the current price target is an average from 2 analysts. New target price is 2,017% above last closing price of US$1.49. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$5.63 next year compared to a net loss per share of US$5.86 last year. Price Target Changed • Oct 13
Price target decreased by 90% to US$4.01 Down from US$40.00, the current price target is provided by 1 analyst. New target price is 177% above last closing price of US$1.45. Stock is down 75% over the past year. The company is forecast to post a net loss per share of US$6.00 next year compared to a net loss per share of US$5.86 last year. Annonce • Oct 11
Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology Aethlon Medical, Inc. announced that it has received clearance from the Drug Controller General of India (DCGI), the central drug authority in India, to conduct a phase 1 safety, feasibility and dose-finding trial of the company's Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda(R) or Opdivo(R). The trial is expected to begin following completion of an internal in vitro binding study of relevant targets, and subsequent approval by the respective Ethics Boards of interested sites in India. The planned oncology trial in India is designed to be a safety study in nine to 18 patients to examine three cohorts of Hemopurifier treatments in patients receiving pembrolizumab (Keytruda) or nivolumab (Opdivo) therapy as standard of care for their malignancy. The trial is designed to include multiple tumor types, as well as Hemopurifier dosing intervals, to help direct further development of the Hemopurifier for use in oncology. The trial's primary endpoint will be to assess the safety and feasibility of the Hemopurifier-treated patients at different treatment intervals in patients with solid tumors with stable or progressive disease after 60 days of pembrolizumab or nivolumab monotherapy. Additionally, the effects of Hemopurifier treatment on the immune response to cancer will be assessed. Annonce • Aug 04
Aethlon Medical, Inc. to Report Q1, 2024 Results on Aug 10, 2023 Aethlon Medical, Inc. announced that they will report Q1, 2024 results at 4:15 PM, Eastern Standard Time on Aug 10, 2023 Annonce • Jul 29
Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023 Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023, at 08:00 Pacific Standard Time. Agenda: To consider directorate elections; to consider ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2024; to consider approve, pursuant to Nevada Revised Statutes 78.2055, a reverse stock split of our common stock at a ratio in the range of 1-for-8 to 1-for-12, with such ratio to be determined in the discretion of our Board of Directors and with such reverse stock split to be effected at such time and date as determined by our Board of Directors in its sole discretion; and to consider transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. Price Target Changed • Jul 07
Price target decreased by 12% to US$6.50 Down from US$7.38, the current price target is an average from 2 analysts. New target price is 1,394% above last closing price of US$0.43. Stock is down 58% over the past year. The company is forecast to post a net loss per share of US$0.53 next year compared to a net loss per share of US$0.59 last year. Annonce • Jul 07
Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee On July 3, 2023, the Board of Directors of Aethlon Medical, Inc., upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Nicolas Gikakis as (i) a member of the Board, and (ii) a member of the Nominating Committee. From 2021 to May 2023, Mr. Gikakis served as the Head of Commercial for WearOptimo Pty Ltd, a private Australian medical device and digital health company. Previously, from 2017 to 2019, Mr. Gikakis was Vice President of Strategy and Corporate Development at Oventus Medical Limited, a private medical device company, during which time he assisted with the commercial expansion of its sleep apnea device. From 2012 to 2021, Mr. Gikakis held various leadership and independent strategic advisor positions in the healthcare industry in sales, marketing, product development, and corporate development and transactions, including for companies working with blood filtration and purification. Mr. Gikakis earned a BS in bioengineering from the University of Pennsylvania and holds an MBA from George Mason University, with earlier work in bench and clinical research, and clinical experience at the University of Pennsylvania. New Risk • Jun 30
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Revenue is less than US$1m (US$574k revenue). Market cap is less than US$10m (US$9.89m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$14m net loss next year). Reported Earnings • Jun 29
Full year 2023 earnings released: US$0.59 loss per share (vs US$0.71 loss in FY 2022) Full year 2023 results: US$0.59 loss per share. Net loss: US$12.0m (loss widened 16% from FY 2022). Revenue is expected to decline by 171% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in the US are expected to grow by 7.8%. Annonce • Jun 23
Aethlon Medical, Inc. to Report Q4, 2023 Results on Jun 28, 2023 Aethlon Medical, Inc. announced that they will report Q4, 2023 results at 4:15 PM, US Eastern Standard Time on Jun 28, 2023 New Risk • Jun 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Revenue is less than US$1m (US$13k revenue). Market cap is less than US$10m (US$7.65m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$13m net loss next year). Shareholders have been diluted in the past year (49% increase in shares outstanding). Breakeven Date Change • Feb 17
No longer forecast to breakeven The 2 analysts covering Aethlon Medical no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.81m in 2023. New consensus forecast suggests the company will make a loss of US$13.6m in 2024. Reported Earnings • Feb 14
Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022) Third quarter 2023 results: US$0.12 loss per share. Net loss: US$2.85m (loss widened 13% from 3Q 2022). Revenue is expected to decline by 124% p.a. on average during the next 3 years, while revenues in the Medical Equipment industry in the US are expected to grow by 7.5%. Annonce • Feb 07
Aethlon Medical, Inc. to Report Q3, 2023 Results on Feb 13, 2023 Aethlon Medical, Inc. announced that they will report Q3, 2023 results at 4:15 PM, US Eastern Standard Time on Feb 13, 2023 Breakeven Date Change • Feb 02
Forecast to breakeven in 2023 The 3 analysts covering Aethlon Medical expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$5.81m in 2023. Breakeven Date Change • Nov 19
No longer forecast to breakeven The 2 analysts covering Aethlon Medical no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2023. New consensus forecast suggests the company will make a loss of US$14.7m in 2024. Reported Earnings • Nov 16
First half 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 1H 2022) First half 2023 results: US$0.37 loss per share (further deteriorated from US$0.29 loss in 1H 2022). Net loss: US$6.71m (loss widened 64% from 1H 2022). Revenue is expected to decline by 64% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in the US are expected to grow by 7.4%. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Breakeven Date Change • Aug 13
Forecast to breakeven in 2023 The 2 analysts covering Aethlon Medical expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$17.1m in 2023. Reported Earnings • Aug 11
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2023 results: US$0.19 loss per share (down from US$0.16 loss in 1Q 2022). Net loss: US$2.91m (loss widened 39% from 1Q 2022). Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 14%. Over the next year, revenue is expected to shrink by 17% compared to a 6.3% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Major Estimate Revision • Jul 05
Consensus revenue estimates fall by 100% The consensus outlook for revenues in 2023 has deteriorated. 2023 revenue forecast decreased from US$47.7m to US$170.0k. Forecast loss of -US$0.88, down from profit of US$0.83 per share profit previously. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$7.00 unchanged from last update. Share price fell 14% to US$1.01 over the past week. Price Target Changed • Apr 27
Price target decreased to US$7.00 Down from US$9.33, the current price target is an average from 2 analysts. New target price is 531% above last closing price of US$1.11. Stock is down 40% over the past year. The company is forecast to post a net loss per share of US$0.60 next year compared to a net loss per share of US$0.65 last year. Major Estimate Revision • Apr 27
Consensus revenue estimates increase by 178% The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$360.0k to US$1.01m. Forecast losses expected to reduce from -US$0.62 to -US$0.60 per share. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target of US$7.00 unchanged from last update. Share price fell 11% to US$1.11 over the past week. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Senior VP, Chief Business Officer & Director Guy Cipriani was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Major Estimate Revision • Apr 22
Consensus revenue estimates increase by 178% The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$360.0k to US$1.01m. Forecast losses expected to reduce from -US$0.62 to -US$0.60 per share. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target of US$7.00 unchanged from last update. Share price fell 4.0% to US$1.19 over the past week. Major Estimate Revision • Feb 22
Consensus revenue estimates fall by 68% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$1.14m to US$360.0k. Forecast losses increased from -US$0.56 to -US$0.62 per share. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target down from US$9.33 to US$7.00. Share price fell 2.1% to US$1.37 over the past week. Board Change • Dec 05
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Senior VP, Chief Business Officer & Director Guy Cipriani was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Major Estimate Revision • Aug 17
Consensus revenue estimates fall to US$1.24m The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$1.46m to US$1.24m. Forecast losses increased from -US$0.51 to -US$0.63 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target of US$9.33 unchanged from last update. Share price fell 33% to US$3.53 over the past week. Reported Earnings • Jun 28
Full year 2021 earnings released: US$0.65 loss per share (vs US$1.87 loss in FY 2020) Full year 2021 results: Net loss: US$7.89m (loss widened 24% from FY 2020). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Breakeven Date Change • Jun 03
Forecast to breakeven in 2023 The 3 analysts covering Aethlon Medical expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$38.8m in 2023. Average annual earnings growth of 43% is required to achieve expected profit on schedule. Analyst Estimate Surprise Post Earnings • Feb 12
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 525%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Over the next year, revenue is expected to shrink by 41% compared to a 21% growth forecast for the Medical Equipment industry in the US. Is New 90 Day High Low • Feb 09
New 90-day high: US$2.81 The company is up 92% from its price of US$1.46 on 10 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 7.0% over the same period. Recent Insider Transactions • Dec 21
Independent Director recently sold US$57k worth of stock On the 17th of December, Chetan Shah sold around 27k shares on-market at roughly US$2.11 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. 